36 results on '"Holm, Anja"'
Search Results
2. Protein kinase C-inhibition reduces critical weight loss and improves functional outcome after experimental subarachnoid haemorrhage
- Author
-
Bömers, Jesper P, Holm, Anja, Kazantzi, Spyridoula, Edvinsson, Lars, Mathiesen, Tiit I, and Haanes, Kristian A
- Published
- 2024
- Full Text
- View/download PDF
3. Heterogeneous vasomotor responses in segments from Göttingen Minipigs coronary, cerebral, and mesenteric artery: A comparative study
- Author
-
Sams, Anette, Haanes, Kristian Agmund, Holm, Anja, Kazantzi, Spyridoula, Mikkelsen, Lars Friis, Edvinsson, Lars, Brain, Susan, and Sheykhzade, Majid
- Published
- 2023
- Full Text
- View/download PDF
4. Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin
- Author
-
Berhane, Tsinat, Holm, Anja, Karstensen, Kasper Thystrup, Petri, Andreas, Ilieva, Mirolyuba Simeonova, Krarup, Henrik, Vyberg, Mogens, Løvendorf, Marianne Bengtson, and Kauppinen, Sakari
- Published
- 2022
- Full Text
- View/download PDF
5. Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses.
- Author
-
Birkmann, Katharina, Jebbawi, Fadi, Waldern, Nina, Hug, Sophie, Inversini, Victoria, Keller, Giulia, Holm, Anja, Grest, Paula, Canonica, Fabia, Schmid-Grendelmeier, Peter, and Fettelschoss-Gabriel, Antonia
- Subjects
EOSINOPHILS ,HORSES ,URTICARIA ,SHOW horses ,HORSE shows ,SYMPTOMS ,SEASONAL variations of diseases - Abstract
Urticaria, independent of or associated with allergies, is commonly seen in horses and often shows a high reoccurrence rate. Managing these horses is discouraging, and efficient treatment options are lacking. Due to an incidental finding in a study on horses affected by insect bite hypersensitivity using the eosinophil-targeting eIL-5-CuMV-TT vaccine, we observed the prevention of reoccurring seasonal urticaria in four subsequent years with re-vaccination. In an exploratory case series of horses affected with non-seasonal urticaria, we aimed to investigate the role of eosinophils in urticaria. Skin punch biopsies for histology and qPCR of eosinophil associated genes were performed. Further, two severe, non-seasonal, recurrent urticaria-affected horses were vaccinated using eIL-5-CuMV-TT, and urticaria flare-up was followed up with re-vaccination for several years. Eotaxin-2, eotaxin-3, IL-5, CCR5, and CXCL10 showed high sensitivity and specificity for urticarial lesions, while eosinophils were present in 50% of histological tissue sections. The eIL-5-CuMV-TT vaccine reduced eosinophil counts in blood, cleared clinical signs of urticaria, and even prevented new episodes of urticaria in horses with non-seasonal recurrent urticaria. This indicates that eosinophils play a leading role in urticaria in horses, and targeting eosinophils offers an attractive new treatment option, replacing the use of corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. The old, unique C1 chondrite Flensburg – Insight into the first processes of aqueous alteration, brecciation, and the diversity of water-bearing parent bodies and lithologies
- Author
-
Bischoff, Addi, Alexander, Conel M. O'D., Barrat, Jean-Alix, Burkhardt, Christoph, Busemann, Henner, Degering, Detlev, Di Rocco, Tommaso, Fischer, Meike, Fockenberg, Thomas, Foustoukos, Dionysis I., Gattacceca, Jérôme, Godinho, Jose R.A., Harries, Dennis, Heinlein, Dieter, Hellmann, Jan L., Hertkorn, Norbert, Holm, Anja, Jull, A.J. Timothy, Kerraouch, Imene, King, Ashley J., Kleine, Thorsten, Koll, Dominik, Lachner, Johannes, Ludwig, Thomas, Merchel, Silke, Mertens, Cornelia A.K., Morino, Précillia, Neumann, Wladimir, Pack, Andreas, Patzek, Markus, Pavetich, Stefan, Reitze, Maximilian P., Rüfenacht, Miriam, Rugel, Georg, Schmidt, Charlotte, Schmitt-Kopplin, Philippe, Schönbächler, Maria, Trieloff, Mario, Wallner, Anton, Wimmer, Karl, and Wölfer, Elias
- Published
- 2021
- Full Text
- View/download PDF
7. RNA therapeutics for epilepsy: An emerging modality for drug discovery.
- Author
-
Hansen, Stine N., Holm, Anja, Kauppinen, Sakari, and Klitgaard, Henrik
- Subjects
- *
DRUG discovery , *LINCRNA , *EPILEPSY , *CIRCULAR RNA , *CHILDHOOD epilepsy - Abstract
Drug discovery in epilepsy began with the finding of potassium bromide by Sir Charles Locock in 1857. The following century witnessed the introduction of phenotypic screening tests for discovering antiseizure medications (ASMs). Despite the high success rate of developing ASMs, they have so far failed in eliminating drug resistance and in delivering disease‐modifying treatments. This emphasizes the need for new drug discovery strategies in epilepsy. RNA‐based drugs have recently shown promise as a new modality with the potential of providing disease modification and counteracting drug resistance in epilepsy. RNA therapeutics can be directed either toward noncoding RNAs, such as microRNAs, long noncoding RNAs (ncRNAs), and circular RNAs, or toward messenger RNAs. The former show promise in sporadic, nongenetic epilepsies, as interference with ncRNAs allows for modulation of entire disease pathways, whereas the latter seem more promising in monogenic childhood epilepsies. Here, we describe therapeutic strategies for modulating disease‐associated RNA molecules and highlight the potential of RNA therapeutics for the treatment of different patient populations such as sporadic, drug‐resistant epilepsy, and childhood monogenic epilepsies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Absence of autoreactive CD4+ T-cells targeting HLA-DQA1*01:02/DQB1*06:02 restricted hypocretin/orexin epitopes in narcolepsy type 1 when detected by EliSpot
- Author
-
Kornum, Birgitte Rahbek, Burgdorf, Kristoffer Sølvsten, Holm, Anja, Ullum, Henrik, Jennum, Poul, and Knudsen, Stine
- Published
- 2017
- Full Text
- View/download PDF
9. Intraocular Adeno-Associated Virus-Mediated Transgene Endothelin-1 Delivery to the Rat Eye Induces Functional Changes Indicative of Retinal Ischemia—A Potential Chronic Glaucoma Model.
- Author
-
Nordahl, Karin M. L., Fedulov, Vadim, Holm, Anja, and Haanes, Kristian A.
- Subjects
PREPROENDOTHELIN ,CALCITONIN gene-related peptide ,TRANSGENE expression ,ISCHEMIA ,INTRAVITREAL injections - Abstract
Endothelin-1 (ET-1) overactivity has been implicated as a factor contributing to glaucomatous neuropathy, and it has been utilized in animal models of retinal ischemia. The functional effects of long-term ET-1 exposure and possible compensatory mechanisms have, however, not been investigated. This was therefore the purpose of our study. ET-1 was delivered into rat eyes via a single intravitreal injection of 500 µM or via transgene delivery using an adeno-associated viral (AAV) vector. Retinal function was assessed using electroretinography (ERG) and the retinal expression of potentially compensatory genes was evaluated by means of qRT-PCR. Acute ET-1 delivery led to vasoconstriction and a significant reduction in the ERG response. AAV–ET-1 resulted in substantial transgene expression and ERG results similar to the acute ET-1 injections and comparable to other models of retinal ischemia. Compensatory changes were observed, including an increase in calcitonin gene-related peptide (CGRP) gene expression, which may both counterbalance the vasoconstrictive effects of ET-1 and provide neuroprotection. This chronic ET-1 ischemia model might be especially relevant to glaucoma research, mimicking the mild and repeated ischemic events in patients with long-term vascular dysfunction. The compensatory mechanisms, and particularly the role of vasodilatory CGRP in mitigating the retinal damage, warrant further investigation with the aim of evaluating new therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health
- Author
-
Catry, Boudewijn, Cavaleri, Marco, Baptiste, Keith, Grave, Kari, Grein, Kornelia, Holm, Anja, Jukes, Helen, Liebana, Ernesto, Navas, Antonio Lopez, Mackay, David, Magiorakos, Anna-Pelagia, Romo, Miguel Angel Moreno, Moulin, Gérard, Madero, Cristina Muñoz, Pomba, Maria Constança Matias Ferreira, Powell, Mair, Pyörälä, Satu, Rantala, Merja, Ružauskas, Modestas, Sanders, Pascal, Teale, Christopher, Threlfall, Eric John, Törneke, Karolina, van Duijkeren, Engeline, and Edo, Jordi Torren
- Published
- 2015
- Full Text
- View/download PDF
11. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens
- Author
-
Pedersen, Natasja Wulff, Holm, Anja, Kristensen, Nikolaj Pagh, Bjerregaard, Anne-Mette, Bentzen, Amalie Kai, Marquard, Andrea Marion, Tamhane, Tripti, Burgdorf, Kristoffer Sølvsten, Ullum, Henrik, Jennum, Poul, Knudsen, Stine, Hadrup, Sine Reker, and Kornum, Birgitte Rahbek
- Published
- 2019
- Full Text
- View/download PDF
12. At the frontiers of animal health: a European perspective: In animal health, as in human health, scientific discoveries and technological innovations are constantly presenting new possibilities for the prevention and treatment of disease; however, these innovative products pose particular challenges
- Author
-
Holm, Anja and Canning, Pascale
- Subjects
Therapeutics ,Business ,Chemicals, plastics and rubber industries ,Engineering and manufacturing industries ,Business, international - Abstract
A large proportion of them originate in academia, research organisations or SMEs that often do not have experienced regulatory personnel nor dedicated internal processes to develop their discoveries. There is [...]
- Published
- 2018
13. Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy
- Author
-
Jørgen Jennum, Poul, Østergaard Pedersen, Lars, Czarna Bahl, Justyna Maria, Modvig, Signe, Fog, Karina, Holm, Anja, Rahbek Kornum, Birgitte, and Gammeltoft, Steen
- Published
- 2017
- Full Text
- View/download PDF
14. The Non-Coding RNA Journal Club: Highlights on Recent Papers—12.
- Author
-
Shiu, Patrick K. T., Ilieva, Mirolyuba, Holm, Anja, Uchida, Shizuka, DiStefano, Johanna K., Bronisz, Agnieszka, Yang, Ling, Asahi, Yoh, Goel, Ajay, Yang, Liuqing, Nuthanakanti, Ashok, Serganov, Alexander, Alahari, Suresh K., Lin, Chunru, Pardini, Barbara, Naccarati, Alessio, Jin, Jing, Armanios, Beshoy, Zhong, Xiao-bo, and Sideris, Nikolaos
- Subjects
NON-coding RNA ,CIRCULAR RNA ,LINCRNA ,QUORUM sensing ,RNA-binding proteins ,HISTOCOMPATIBILITY class I antigens - Published
- 2023
- Full Text
- View/download PDF
15. Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides.
- Author
-
Løvendorf, Marianne Bengtson, Holm, Anja, Petri, Andreas, Thrue, Charlotte Albæk, Uchida, Shizuka, Venø, Morten T., and Kauppinen, Sakari
- Published
- 2023
- Full Text
- View/download PDF
16. Stem-cell Breakthrough in the EU.
- Author
-
Holm, Anja
- Subjects
ANIMAL health - Abstract
The article focuses on a significant advancement in stem-cell research within the European Union, highlighting the groundbreaking nature of this development and its potential to revolutionize treatments for various animal diseases. Topics include the implications for veterinary medicine, regulatory considerations, and potential applications in animal health.
- Published
- 2023
17. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
- Author
-
Christensen, Lise Lotte, Tobiasen, Heidi, Holm, Anja, Schepeler, Troels, Ostenfeld, Marie S, Thorsen, Kasper, Rasmussen, Mads H., Birkenkamp-Demtroeder, Karin, Sieber, Oliver M., Gibbs, Peter, Lubinski, Jan, Lamy, Philippe, Laurberg, Sren, ster, Bodil, Hansen, Kristian Q., Hagemann-Madsen, Rikke, Byskov, Kristina, rntoft, Torben F., and Andersen, Claus L.
- Published
- 2013
- Full Text
- View/download PDF
18. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
- Author
-
Holm, Anja, Hansen, Stine N., Klitgaard, Henrik, and Kauppinen, Sakari
- Published
- 2022
- Full Text
- View/download PDF
19. Survey of 800+ datasets from human tissue and body fluid reveals XenomiRs are likely artifacts
- Author
-
Kang, Wenjing, Bang-Berthelsen, Claus Heiner, Holm, Anja, Houben, Anna, Muller, Anne Holt, Thymann, Thomas, Pociot, Flemming, Estivill, Xavier, and Riemer Friedländer, Marc
- Subjects
Contamination ,Next generation sequencing ,Meta-study ,Artifacts ,miRNA - Abstract
miRNAs are small 22 nucleotide RNAs that can post-transcriptionally regulate gene expression. It has been proposed that dietary plant miRNAs can enter the human bloodstream and regulate host transcripts, however these findings have been widely disputed. We here conduct the first comprehensive meta-study in the field, surveying the presence and abundances of cross-species miRNAs (xenomiRs) in 824 sequencing datasets from various human tissues and body fluids. We find that xenomiRs are commonly present in tissues (17%) and body fluids (69%), however the abundances are low, comprising 0.001% of host human miRNA counts. Further, we do not detect a significant enrichment of xenomiRs in sequencing data originating from tissues and body fluids that are exposed to dietary intake (such as liver). Likewise, there is no significant depletion of xenomiRs in tissues and body fluids that are relatively separated from the main bloodstream (such as brain and cerebro-spinal fluids). Interestingly, the majority (81%) of body fluid xenomiRs stem from rodents, which are rare human dietary contributions, but common laboratory animals. Body fluid samples from the same studies tend to group together when clustered by xenomiR compositions, suggesting technical batch effects. Last, we performed carefully designed and controlled animal feeding studies, in which we detected no transfer of plant miRNAs into rat blood, or bovine milk sequences into piglet blood. In summary, our comprehensive computational and experimental results indicate that xenomiRs originate from technical artifacts rather than dietary intake.
- Published
- 2017
20. Survey of 800+ data sets from human tissue and body fluid reveals xenomiRs are likely artifacts
- Author
-
Kang, Wenjing, Bang-Berthelsen, Claus Heiner, Holm, Anja, Houben, Anna J.S., Müller, Anne Holt, Thymann, Thomas, Pociot, Flemming, Estivill, Xavier, and Friedländer, Marc R.
- Subjects
Contamination ,Exogenous miRNAs ,Meta-study ,Next-generation sequencing ,MicroRNA ,Artifacts ,MiRNA - Abstract
miRNAs are small 22-nucleotide RNAs that can post-transcriptionally regulate gene expression. It has been proposed that dietary plant miRNAs can enter the human bloodstream and regulate host transcripts; however, these findings have been widely disputed. We here conduct the first comprehensive meta-study in the field, surveying the presence and abundances of cross-species miRNAs (xenomiRs) in 824 sequencing data sets from various human tissues and body fluids. We find that xenomiRs are commonly present in tissues (17%) and body fluids (69%); however, the abundances are low, comprising 0.001% of host human miRNA counts. Further, we do not detect a significant enrichment of xenomiRs in sequencing data originating from tissues and body fluids that are exposed to dietary intake (such as liver). Likewise, there is no significant depletion of xenomiRs in tissues and body fluids that are relatively separated from the main bloodstream (such as brain and cerebro-spinal fluids). Interestingly, the majority (81%) of body fluid xenomiRs stem from rodents, which are a rare human dietary contribution but common laboratory animals. Body fluid samples from the same studies tend to group together when clustered by xenomiR compositions, suggesting technical batch effects. Last, we performed carefully designed and controlled animal feeding studies, in which we detected no transfer of plant miRNAs into rat blood, or bovine milk sequences into piglet blood. In summary, our comprehensive computational and experimental results indicate that xenomiRs originate from technical artifacts rather than dietary intake.
- Published
- 2017
21. Obstacles to vaccination of animals and prospective solutions.
- Author
-
Holm, Anja and Kortekaas, Jeroen
- Subjects
- *
ANIMAL vaccination , *MIDDLE-income countries , *LOW-income countries , *VACCINES industry , *GENETIC code - Abstract
On the 17th of October 2019, a workshop was held at Wageningen Bioveterinary Research in Lelystad, the Netherlands, to discuss the obstacles to vaccination in the veterinary field. Participants from academia, OIE, FAO, EC, EMA, USDA, national regulatory and veterinary health authorities, and the animal health industry discussed how availability and access to animal vaccines can be improved not just in the EU and US but also in Low to Middle Income Countries (LMIC) across the world and agreed that this requires innovations in both the scientific and the regulatory field. The workshop called for engaging all stakeholders to improve regulatory acceptance of novel vaccine technologies and encourage their registration. There is a need for better mutual understanding between academia, industry and regulators, and more openness to discuss framework, requirements, and product authorisations, and to converge the regulatory rules between regions. The next leap forward could be a broader application of novel technologies using RNA- or DNA-based vaccine platforms, where the "backbone" is maintained, while the gene of interest coding for an immunogenic protein can be exchanged in a standardised manner. This approach enables rapid response in outbreak situations and should lower the risk and cost of vaccine development. • A workshop on safe, efficacious, affordable, and rapidly adaptable vaccines for emerging, epizootic and enzootic diseases. • RNA- or DNA-based vaccine platforms, with maintained backbone and interchangeable gene of interest, are promising. • Regulatory guidance is needed, keeping requirements and costs proportionate to the small size of veterinary markets. • Early dialogue and cooperation between regulatory authorities, academia and vaccine industry was emphasised for success. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. New paths for sustainable solutions to tackle global and emerging infectious threats.
- Author
-
Holm, Anja
- Subjects
- *
AFRICAN swine fever , *VETERINARY vaccines , *AFRICAN swine fever virus , *ANIMAL populations , *POPULATION , *COMMUNICABLE diseases - Abstract
With the dramatic background of a newly emerged virus (SARS-CoV-2) spreading around the world, Coronavirus and other infectious health threats for the human and animal populations were illustrated and debated in excellent presentations at the IABS meeting 26–28 of February 2020. Historical evidence of pandemics and lessons learned from recent epidemics or epizootics caused by many pathogens (e.g., Ebola, Zika, and African Swine Fever viruses) illustrated the overarching need for close international cooperation. New and old technologies in vaccine development and their use were presented, resulting in a call for greater interaction between the human and the veterinary fields in order to leverage the expertise and knowledge in both human and animal medicine. The One Health concept was also emphasized for eliminating the 59,000 fatal human rabies cases annually attributed to unvaccinated dogs. For preventable, infectious diseases commonly spreading in the poorer regions of the world, a new regulatory approach and governance structure was called for to give access to affordable vaccines. Vaccines were touted as one of the most successful health invention ever introduced; on a similar level to health improvements due to clean water. • The IABS anniversary meeting in Lyon 26–28 Feb 2020 presented solutions to tackle global and emerging infectious threats. • Lessons from recent epidemics or epizootics (e.g. Ebola, Zika, ASF) illustrated the need for close international cooperation. • Greater interaction between the human and veterinary stakeholders could leverage the expertise and knowledge in both fields. • The socio-economic benefit of vaccination was demonstrated for health, education, productivity, poverty, and macroeconomy. • An improved governance structure was called for to facilitate affordable vaccines in all regions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Diagnostics in the veterinary field: The role in health surveillance and disease identification
- Author
-
Holm, Anja, Hill, Richard, Farsang, Attila, and Jungbäck, Carmen
- Published
- 2019
- Full Text
- View/download PDF
24. Absence of autoreactive CD4+ T-cells targeting HLA-DQA1*01:02/DQB1*06:02 restricted hypocretin/orexin epitopes in narcolepsy type 1 when detected by EliSpot.
- Author
-
Holm, Anja, Kornum, Birgitte Rahbek, Jennum, Poul, Knudsen, Stine, Burgdorf, Kristoffer Sølvsten, and Ullum, Henrik
- Subjects
- *
CD4 lymphocyte count , *NARCOLEPSY , *HLA histocompatibility antigens , *NEUROPEPTIDES , *OREXINS - Abstract
Narcolepsy type 1, a neurological sleep disorder strongly associated with Human Leukocyte Antigen (HLA-)DQB1*06:02, is caused by the loss of hypothalamic neurons producing the wake-promoting neuropeptide hypocretin (hcrt, also known as orexin). This loss is believed to be caused by an autoimmune reaction. To test whether hcrt itself could be a possible target in the autoimmune attack, CD4 + T-cell reactivity towards six different 15-mer peptides from prepro-hypocretin with high predicted affinity to the DQA1*01:02/DQB1*06:02 MHC class II dimer was tested using EliSpot in a cohort of 22 narcolepsy patients with low CSF hcrt levels, and 23 DQB1*06:02 positive healthy controls. Our ELISpot assay had a detection limit of 1:10,000 cells. We present data showing that autoreactive CD4 + T-cells targeting epitopes from the hcrt precursor in the context of MHC-DQA1*01:02/DQB1*06:02 are either not present or present in a frequency is < 1:10,000 among peripheral CD4 + T-cells from narcolepsy type 1 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. EIF3G is associated with narcolepsy across ethnicities.
- Author
-
Holm, Anja, Lin, Ling, Faraco, Juliette, Mostafavi, Sara, Battle, Alexis, Zhu, Xiaowei, Levinson, Douglas F, Han, Fang, Gammeltoft, Steen, Jennum, Poul, Mignot, Emmanuel, and Kornum, Birgitte R
- Subjects
- *
NARCOLEPSY , *OREXINS , *SINGLE nucleotide polymorphisms , *DNA methyltransferases , *GENETICS of deafness , *CEREBELLAR ataxia , *DEMENTIA , *MESSENGER RNA , *GENETICS - Abstract
Type 1 narcolepsy, an autoimmune disease affecting hypocretin (orexin) neurons, is strongly associated with HLA-DQB1*06:02. Among polymorphisms associated with the disease is single-nucleotide polymorphism rs2305795 (c.*638G>A) located within the P2RY11 gene. P2RY11 is in a region of synteny conserved in mammals and zebrafish containing PPAN, EIF3G and DNMT1 (DNA methyltransferase 1). As mutations in DNMT1 cause a rare dominant form of narcolepsy in association with deafness, cerebellar ataxia and dementia, we questioned whether the association with P2RY11 in sporadic narcolepsy could be secondary to linkage disequilibrium with DNMT1. Based on genome-wide association data from two cohorts of European and Chinese ancestry, we found that the narcolepsy association signal drops sharply between P2RY11/EIF3G and DNMT1, suggesting that the association with narcolepsy does not extend into the DNMT1 gene region. Interestingly, using transethnic mapping, we identified a novel single-nucleotide polymorphism rs3826784 (c.596-260A>G) in the EIF3G gene also associated with narcolepsy. The disease-associated allele increases EIF3G mRNA expression. EIF3G is located in the narcolepsy risk locus and EIF3G expression correlates with PPAN and P2RY11 expression. This suggests shared regulatory mechanisms that might be affected by the polymorphism and are of relevance to narcolepsy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. miRNA profiles in cerebrospinal fluid from patients with central hypersomnias.
- Author
-
Holm, Anja, Bang-Berthelsen, Claus Heiner, Knudsen, Stine, Modvig, Signe, Kornum, Birgitte Rahbek, Gammeltoft, Steen, and Jennum, Poul J.
- Subjects
- *
MICRORNA , *CEREBROSPINAL fluid examination , *HYPERSOMNIA , *NARCOLEPSY , *CENTRAL nervous system , *COHORT analysis , *DIAGNOSIS - Abstract
MicroRNAs (miRNAs) are involved in the pathogenesis of many human diseases, including some neurological disorders. Recently, we have reported dysregulated miRNAs in plasma from patients with central hypersomnias including type 1 and type 2 narcolepsy, and idiopathic hypersomnia. This study addressed whether miRNA levels are altered in the cerebrospinal fluid (CSF) of patients with central hypersomnias. We conducted high-throughput analyses of miRNAs in CSF from patients using quantitative real-time polymerase chain reaction panels. We identified 13, 9, and 11 miRNAs with a more than two-fold change in concentration in CSF from patients with type 1 and type 2 narcolepsy and idiopathic hypersomnia, respectively, compared with matched healthy controls. Most miRNAs differed in more than one of the sleep disorders. However, all miRNAs were detected at low levels in CSF and varied between individuals. None of them showed significant differences in concentrations between groups after correcting for multiple testing, and none could be validated in an independent cohort. Nevertheless, approximately 60% of the most abundant miRNAs in the profile reported here have previously been identified in the CSF of healthy individuals, showing consistency with previous miRNA profiles found in CSF. In conclusion, we were not able to demonstrate distinct levels or patterns of miRNAs in CSF from central hypersomnia patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. miRNA Profiles in Plasma from Patients with Sleep Disorders Reveal Dysregulation of miRNAs in Narcolepsy and Other Central Hypersomnias.
- Author
-
Holm, Anja, Bang-Berthelsen, Claus Heiner, Knudsen, Stine, Kornum, Birgitte R, Modvig, Signe, Jennum, Poul, and Gammeltoft, Steen
- Published
- 2014
- Full Text
- View/download PDF
28. Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer.
- Author
-
Christensen, Lise Lotte, Holm, Anja, Rantala, Juha, Kallioniemi, Olli, Rasmussen, Mads H., Ostenfeld, Marie S., Dagnaes-Hansen, Frederik, Øster, Bodil, Schepeler, Troels, Tobiasen, Heidi, Thorsen, Kasper, Sieber, Oliver M., Gibbs, Peter, Lamy, Philippe, Hansen, Torben F., Jakobsen, Anders, Riising, Eva M., Helin, Kristian, Lubinski, Jan, and Hagemann-Madsen, Rikke
- Subjects
- *
COLON cancer diagnosis , *COLON cancer prognosis , *MICRORNA genetics , *CANCER cell proliferation , *APOPTOSIS , *CANCER cell culture , *GENE libraries - Abstract
MicroRNAs (miRNAs) play a critical role in many biological processes and are aberrantly expressed in human cancers. Particular miRNAs function either as tumor suppressors or oncogenes and appear to have diagnostic and prognostic significance. Although numerous miRNAs are dys-regulated in colorectal cancer (CRC) only a small fraction has been characterized functionally. Using high-throughput functional screening and miRNA profiling of clinical samples the present study aims at identifying miRNAs important for the control of cellular growth and/or apoptosis in CRC. The high-throughput functional screening was carried out in six CRC cell lines transfected with a pre-miR library including 319 synthetic human pre-miRs. Phenotypic alterations were evaluated by immunostaining of cleaved cPARP (apoptosis) or MKI67 (proliferation). Additionally, TaqMan Human MicroRNA Array Set v2.0 was used to profile the expression of 667 miRNAs in 14 normal colon mucosa and 46 microsatellite stable stage II CRC patients. Among the miRNAs that induced growth arrest and apoptosis in the CRC cell lines, and at same time were dys-regulated in the clinical samples, miR-375 was selected for further analysis. Independent in vitro analysis of transient and stable transfected CRC cell lines confirmed that miR-375 reduces cell viability through the induction of apoptotic death. We identified YAP1 as a direct miR-375 target in CRC and show that HELLS and NOLC1 are down-stream targets. Knock-down of YAP1 mimicked the phenotype induced by miR-375 over-expression indicating that miR-375 most likely exerts its pro-apoptotic role through YAP1 and its anti-apoptotic down-stream targets BIRC5 and BCL2L1. Finally, in vivo analysis of mouse xenograft tumors showed that miR-375 expression significantly reduced tumor growth. We conclude that the high-throughput screening successfully identified miRNAs that induce apoptosis and/or inhibit proliferation in CRC cells. Finally, combining the functional screening with profiling of CRC tissue samples we identified clinically relevant miRNAs and miRNA targets in CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens.
- Author
-
Pedersen, Natasja Wulff, Holm, Anja, Kristensen, Nikolaj Pagh, Bjerregaard, Anne-Mette, Bentzen, Amalie Kai, Marquard, Andrea Marion, Tamhane, Tripti, Burgdorf, Kristoffer Sølvsten, Ullum, Henrik, Jennum, Poul, Knudsen, Stine, Hadrup, Sine Reker, and Kornum, Birgitte Rahbek
- Abstract
Narcolepsy Type 1 (NT1) is a neurological sleep disorder, characterized by the loss of hypocretin/orexin signaling in the brain. Genetic, epidemiological and experimental data support the hypothesis that NT1 is a T-cell-mediated autoimmune disease targeting the hypocretin producing neurons. While autoreactive CD4
+ T cells have been detected in patients, CD8+ T cells have only been examined to a minor extent. Here we detect CD8+ T cells specific toward narcolepsy-relevant peptides presented primarily by NT1-associated HLA types in the blood of 20 patients with NT1 as well as in 52 healthy controls, using peptide-MHC-I multimers labeled with DNA barcodes. In healthy controls carrying the disease-predisposing HLA-DQB1*06:02 allele, the frequency of autoreactive CD8+ T cells was lower as compared with both NT1 patients and HLA-DQB1*06:02-negative healthy individuals. These findings suggest that a certain level of CD8+ T-cell reactivity combined with HLA-DQB1*06:02 expression is important for NT1 development. Autoreactive T cells are suspected to destroy hypocretin-producing neurons in narcolepsy. Here the authors detect CD8 T cells recognizing narcolepsy-related proteins in healthy individuals and in patients with narcolepsy, and show that the frequency of self-reactive CD8 T cells differs between patients and controls sharing the same HLA-II risk allele. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
30. The old, unique C1 chondrite Flensburg – Insight into the first processes of aqueous alteration, brecciation, and the diversity of water-bearing parent bodies and lithologies
- Author
-
Bischoff, Addi, Alexander, Conel M. O’D., Barrat, Jean-Alix, Burkhardt, Christoph, Busemann, Henner, Degering, Detlev, Di Rocco, Tommaso, Fischer, Meike, Fockenberg, Thomas, Foustoukos, Dionysis I., Gattacceca, Jérome, Godinho, Jose R.A., Harries, Dennis, Heinlein, Dieter, Hellmann, Jan L., Hertkorn, Norbert, Holm, Anja, Jull, Anthony J.Timothy, Kerraouch, Imene, King, Ashley J., Kleine, Thorsten, Koll, Dominik, Lachner, Johannes, Ludwig, Thomas, Merchel, Silke, Mertens, Cornelia A.K., Morino, Précillia, Neumann, Wladimir, Pack, Andreas, Patzek, Markus, Pavetich, Stefan, Reitze, Maximilian P., Rüfenacht, Miriam, Rugel, Georg, Schmidt, Charlotte, Schmitt-Kopplin, Philippe, Schönbächler, Maria, Trieloff, Mario, Wallner, Anton, Wimmer, Karl, and Wölfer, Elias
- Subjects
Unique chondrite ,13. Climate action ,Carbonaceous chondrite ,Carbonates ,Oldest carbonates in solar system ,C1 chondrite ,Aqueous alteration ,Early solar system ,Ungrouped C chondrite - Abstract
On September 12, 2019 at 12:49:48 (UT) a bolide was observed by hundreds of eye-witnesses from the Netherlands, Germany, Belgium, Denmark and the UK. One day later a small meteorite stone was found by accident in Flensburg. The presence of short-lived cosmogenic radionuclides with half-lives as short as 16 days proves the recent exposure of the found object to cosmic rays in space linking it clearly to the bolide event. An exceptionally short exposure time of ∼5000 years was determined. The 24.5 g stone has a fresh black fusion crust, a low density of, Geochimica et Cosmochimica Acta, 293, ISSN:0016-7037, ISSN:1872-9533
31. Diagnostics in the veterinary field: The role in health surveillance and disease identification.
- Author
-
Hill, Richard, Farsang, Attila, Jungbäck, Carmen, and Holm, Anja
- Subjects
- *
ACCELERATED life testing , *REGIONAL cooperation , *ANIMAL health , *RECEIVER operating characteristic curves , *LABORATORY animals , *RESEARCH & development , *SURVEYS - Abstract
An international workshop, held in Wiesbaden, Germany on 15–17 May 2019 provided an overview of existing and new methods and approaches to diagnostics in animal health and their benefits and challenges. The variability in quality and authority review of test kits across the world is a concern for the reliability of test results and the decisions that are based on the diagnostic data. In countries or regions without regulatory oversight, there is an urgent need for international harmonisation of quality requirements and licensing procedures. This would increase the validity of the diagnostic methods and allow mutual recognition of test results within the network of official control laboratories and amongst animal health officials. Regional cooperation, as well as the OIE Laboratory Network, should be used to support licensing procedures, pool resources for serum and sample banks, survey outbreak responses, and coordinate research and development of new veterinary diagnostics. The end-users must have clear information on a test's performance, limitations, and interpretation of results. • Veterinary diagnostics show a concerning variability in quality and in authority review. • International harmonisation of quality requirements and licensing procedures are urgently needed. • Regional cooperation could support licensing, outbreak responses, and coordinate research. • Clear information on a test's performance, limitations, and interpretation of results should be available for the end-users. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. The evolutionarily conserved miRNA-137 targets the neuropeptide hypocretin/orexin and modulates the wake to sleep ratio.
- Author
-
Holm A, Possovre ML, Bandarabadi M, Moseholm KF, Justinussen JL, Bozic I, Lemcke R, Arribat Y, Amati F, Silahtaroglu A, Juventin M, Adamantidis A, Tafti M, and Kornum BR
- Subjects
- Animals, Intracellular Signaling Peptides and Proteins genetics, Mice, Orexins genetics, Orexins metabolism, Sleep genetics, Wakefulness genetics, Zebrafish metabolism, MicroRNAs genetics, Neuropeptides metabolism
- Abstract
Hypocretin (Hcrt), also known as orexin, neuropeptide signaling stabilizes sleep and wakefulness in all vertebrates. A lack of Hcrt causes the sleep disorder narcolepsy, and increased Hcrt signaling has been speculated to cause insomnia, but while the signaling pathways of Hcrt are relatively well-described, the intracellular mechanisms that regulate its expression remain unclear. Here, we tested the role of microRNAs (miRNAs) in regulating Hcrt expression. We found that miR-137, miR-637, and miR-654-5p target the human HCRT gene. miR-137 is evolutionarily conserved and also targets mouse Hcrt as does miR-665. Inhibition of miR-137 specifically in Hcrt neurons resulted in Hcrt upregulation, longer episodes of wakefulness, and significantly longer wake bouts in the first 4 h of the active phase. IL-13 stimulation upregulated endogenous miR-137, while Hcrt mRNA decreased both in vitro and in vivo. Furthermore, knockdown of miR-137 in zebrafish substantially increased wakefulness. Finally, we show that in humans, the MIR137 locus is genetically associated with sleep duration. In conclusion, these results show that an evolutionarily conserved miR-137:Hcrt interaction is involved in sleep–wake regulation.
- Published
- 2022
- Full Text
- View/download PDF
33. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
- Author
-
Holm A, Løvendorf MB, and Kauppinen S
- Subjects
- Acetylgalactosamine analogs & derivatives, Acetylgalactosamine therapeutic use, Amyloid Neuropathies, Familial genetics, Amyloid Neuropathies, Familial metabolism, Amyloid Neuropathies, Familial therapy, Animals, Gene Transfer Techniques, Humans, Liver Diseases genetics, Liver Diseases metabolism, Porphyrias, Hepatic diagnosis, Porphyrias, Hepatic metabolism, Porphyrias, Hepatic therapy, Pyrrolidines therapeutic use, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Liver Diseases therapy, RNA Interference, RNA, Small Interfering therapeutic use, RNAi Therapeutics
- Abstract
Small interfering RNA (siRNA)-based therapeutics holds the promise to treat a wide range of human diseases that are currently incurable using conventional therapies. Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent FDA approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively. Here, we describe the current strategies for delivering siRNA drugs to the liver and summarize recent advances in clinical development of siRNA therapeutics for the treatment of liver diseases.
- Published
- 2021
- Full Text
- View/download PDF
34. Survey of 800+ data sets from human tissue and body fluid reveals xenomiRs are likely artifacts.
- Author
-
Kang W, Bang-Berthelsen CH, Holm A, Houben AJ, Müller AH, Thymann T, Pociot F, Estivill X, and Friedländer MR
- Subjects
- Animals, Artifacts, Cattle, High-Throughput Nucleotide Sequencing, Humans, Liver metabolism, MicroRNAs blood, MicroRNAs cerebrospinal fluid, MicroRNAs classification, Plants chemistry, RNA, Plant blood, RNA, Plant cerebrospinal fluid, RNA, Plant classification, Rats, Body Fluids chemistry, Brain Chemistry, Diet, Liver chemistry, MicroRNAs isolation & purification, RNA, Plant isolation & purification
- Abstract
miRNAs are small 22-nucleotide RNAs that can post-transcriptionally regulate gene expression. It has been proposed that dietary plant miRNAs can enter the human bloodstream and regulate host transcripts; however, these findings have been widely disputed. We here conduct the first comprehensive meta-study in the field, surveying the presence and abundances of cross-species miRNAs (xenomiRs) in 824 sequencing data sets from various human tissues and body fluids. We find that xenomiRs are commonly present in tissues (17%) and body fluids (69%); however, the abundances are low, comprising 0.001% of host human miRNA counts. Further, we do not detect a significant enrichment of xenomiRs in sequencing data originating from tissues and body fluids that are exposed to dietary intake (such as liver). Likewise, there is no significant depletion of xenomiRs in tissues and body fluids that are relatively separated from the main bloodstream (such as brain and cerebro-spinal fluids). Interestingly, the majority (81%) of body fluid xenomiRs stem from rodents, which are a rare human dietary contribution but common laboratory animals. Body fluid samples from the same studies tend to group together when clustered by xenomiR compositions, suggesting technical batch effects. Last, we performed carefully designed and controlled animal feeding studies, in which we detected no transfer of plant miRNAs into rat blood, or bovine milk sequences into piglet blood. In summary, our comprehensive computational and experimental results indicate that xenomiRs originate from technical artifacts rather than dietary intake., (© 2017 Kang et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.)
- Published
- 2017
- Full Text
- View/download PDF
35. Normal Morning Melanin-Concentrating Hormone Levels and No Association with Rapid Eye Movement or Non-Rapid Eye Movement Sleep Parameters in Narcolepsy Type 1 and Type 2.
- Author
-
Schrölkamp M, Jennum PJ, Gammeltoft S, Holm A, Kornum BR, and Knudsen S
- Subjects
- Adult, Denmark, Female, Humans, Male, Polysomnography, Sleep, REM physiology, Hypothalamic Hormones blood, Hypothalamic Hormones cerebrospinal fluid, Melanins blood, Melanins cerebrospinal fluid, Narcolepsy blood, Narcolepsy cerebrospinal fluid, Pituitary Hormones blood, Pituitary Hormones cerebrospinal fluid, Sleep physiology
- Abstract
Study Objectives: Other than hypocretin-1 (HCRT-1) deficiency in narcolepsy type 1 (NT1), the neurochemical imbalance of NT1 and narcolepsy type 2 (NT2) with normal HCRT-1 levels is largely unknown. The neuropeptide melanin-concentrating hormone (MCH) is mainly secreted during sleep and is involved in rapid eye movement (REM) and non-rapid eye movement (NREM) sleep regulation. Hypocretin neurons reciprocally interact with MCH neurons. We hypothesized that altered MCH secretion contributes to the symptoms and sleep abnormalities of narcolepsy and that this is reflected in morning cerebrospinal fluid (CSF) MCH levels, in contrast to previously reported normal evening/afternoon levels., Methods: Lumbar CSF and plasma were collected from 07:00 to 10:00 from 57 patients with narcolepsy (subtypes: 47 NT1; 10 NT2) diagnosed according to International Classification of Sleep Disorders, Third Edition (ICSD-3) and 20 healthy controls. HCRT-1 and MCH levels were quantified by radioimmunoassay and correlated with clinical symptoms, polysomnography (PSG), and Multiple Sleep Latency Test (MSLT) parameters., Results: CSF and plasma MCH levels were not significantly different between narcolepsy patients regardless of ICSD-3 subtype, HCRT-1 levels, or compared to controls. CSF MCH and HCRT-1 levels were not significantly correlated. Multivariate regression models of CSF MCH levels, age, sex, and body mass index predicting clinical, PSG, and MSLT parameters did not reveal any significant associations to CSF MCH levels., Conclusions: Our study shows that MCH levels in CSF collected in the morning are normal in narcolepsy and not associated with the clinical symptoms, REM sleep abnormalities, nor number of muscle movements during REM or NREM sleep of the patients. We conclude that morning lumbar CSF MCH measurement is not an informative diagnostic marker for narcolepsy., (© 2017 American Academy of Sleep Medicine)
- Published
- 2017
- Full Text
- View/download PDF
36. Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy.
- Author
-
Jennum PJ, Østergaard Pedersen L, Czarna Bahl JM, Modvig S, Fog K, Holm A, Rahbek Kornum B, and Gammeltoft S
- Subjects
- Adult, Amyloid beta-Peptides cerebrospinal fluid, Case-Control Studies, Chitinase-3-Like Protein 1 cerebrospinal fluid, Female, Humans, Idiopathic Hypersomnia cerebrospinal fluid, Male, Neurofilament Proteins cerebrospinal fluid, Orexins cerebrospinal fluid, alpha-Synuclein cerebrospinal fluid, tau Proteins cerebrospinal fluid, Biomarkers cerebrospinal fluid, Narcolepsy cerebrospinal fluid, Neurodegenerative Diseases cerebrospinal fluid
- Abstract
Objectives: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration., Methods: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1)., Results: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals., Conclusion: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system., (© Sleep Research Society 2016. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.